- Home
- RCKT
as 10-28-2025 2:04am EST
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Upcoming Earnings Alert:
Get ready for potential market movements as Rocket Pharmaceuticals Inc. RCKT prepares to release earnings report on 03 Nov 2025.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 328.6M | IPO Year: | N/A |
| Target Price: | $12.88 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.19 - $18.17 | Next Earning Date: | 11-03-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 3592.74% |
Latest Rocket Pharmaceuticals Inc. News
RCKT Breaking Stock News: Dive into RCKT Ticker-Specific Updates for Smart Investing
Zacks
13 days ago
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy
MT Newswires
14 days ago
Rocket Pharma Gets FDA Review Date for Severe Immune Disorder Drug Candidate
Business Wire
14 days ago
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Business Wire
17 days ago
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
2 months ago
RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study
Clinical Trials Arena
2 months ago
Rocket to relaunch rare disease trial after FDA approval
Barrons.com
2 months ago
Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.
Associated Press Finance
2 months ago
BC-Most Active Stocks
Compare RCKT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RCKT Rocket Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.